A Method for Inhibition of de novo Lipogenesis
This invention provides a method of treating nonalcoholic steatohepatits (NASH), nonalcoholic fatty liver disease (NAFLD), and/or de novo lipogenesis (DNL) in humans. This method may also be used to potentially treat hepatocellular carcinoma.
Researchers at UC San Diego have identified a biochemical pathway responsible for activation of SREBP1/2 in mice suffering from NASH and demonstrates that the same pathway is active in human NASH patients. The invention demonstrates that inhibition of a critical component of this pathway reverses all NASH related symptoms in mice and prevents fat accumulation in liver and enhances energy expenditure.
State Of Development A prototype model has identified a crucial component of the pathway responsible for stimulation of de novo lipogenesis during NAFLD and NASH and have demonstrated its inhibition using a non-proprietary inhibitor which blocks DNA, increases energy expenditure and reverses NASH symptoms in a mouse model. Intellectual Property Info A provisional patent has been submitted. Tech ID/UC Case 27665/2017-157-0 Related Cases 2017-157-0
美國
